Business
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28th International Conference
About this update from Unicycive Therapeutics, Inc.
[{"type":"text","content":"Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT 2023 Conference Highlights key role mitochondria play in disease progression in both acute and chronic kidney injury at 5th Annual Chronic Kidney Disease Drug Development Summit LOS ALTOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the potential of UNI-494, the Company’s proprietary drug that selectively binds to the SUR2B subunit of the mitochondrial KATP channel, will be the focus of several presentations at two upcoming medical and scientific meetings in March 2023. Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will lead a discussion on UNI-494 at the upcoming 5th Annual Chronic Kidney Disease Drug Development Summit taking place in Boston, MA from March 7-9, 2023. Data elucidating how and why mitochondria play a key role in disease progression in both acute and chronic kidney diseases will be highlighted in a presentation titled, “Two Sides of the Same Coin: Targeting AKI in the Framework of CKD,” on Tuesday, March 7, 2023, at 12:00 pm Eastern time.Dr. Gupta’s presentation will include a discussion on predicting patients most likely to develop AKI and those most likely to respond to treatment, along with how to design efficient trials in AKI to optimize therapeutic response. Two abstracts were accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT Conference taking place in San Diego, CA from March 29- April 1, 2023. The following data will be presented at AKI & CRRT: Efficacy data from a study of UNI-494 in an animal model of AKI will be presented in a poster titled, “UNI-494 Lowers Urine 2-microglobulin in Rats.”Safety data from the 28-day oral toxicity study of UNI-494 will be presented in a poster titled “Orally administered UNI-494 is well-tolerated in dogs.” “We are delighted to have the potential of UNI-494 as a treatment for kidney diseases highlighted in multiple medical meetings before audiences of leading kidney disease experts,” said Dr. Gupta. “We are stud...